The role of gut microbiota in immune checkpoint inhibitor therapy

Oncology meets immunology: the cancer-immunity cycle.

Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929 · see citing works

Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors

Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · see citing works

Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells

Furusawa, Y., Obata, Y., Fukuda, S., Endo, T. A., Nakato, G., Takahashi, D., Nakanishi, Y., Uetake, C., Kato, K., Kato, T., et al. (2013) · Nature · doi:10.1038/nature12721 · Cited by 5,549 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients

Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812 · see citing works

Commensal <i>Bifidobacterium</i> promotes antitumor immunity and facilitates anti–PD-L1 efficacy

Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · see citing works

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · see citing works

The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients

Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107 · see citing works

Personalized Gut Mucosal Colonization Resistance to Empiric Probiotics Is Associated with Unique Host and Microbiome Features

Zmora, N., Zilberman-Schapira, G., Suez, J., Mor, U., Dori-Bachash, M., Bashiardes, S., Kotler, E., Zur, M., Regev-Lehavi, D., Brik, R. B.-Z., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.041 · Cited by 1,695 · see citing works

Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab

Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310 · see citing works

Lessons learned from the blockade of immune checkpoints in cancer immunotherapy

Li, X., Shao, C., Shi, Y., & Han, W. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0578-4 · Cited by 385 · see citing works

Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer

Cani, P. D., & Jordan, B. F. (2018) · Nature Reviews Gastroenterology &amp; Hepatology · doi:10.1038/s41575-018-0025-6 · Cited by 383 · see citing works

Gut microbiome modulates efficacy of immune checkpoint inhibitors

Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology &amp; Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179 · see citing works

Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information

Kim, S., Kim, E., Kim, E., Lee, M., Shin, E.-C., Paik, S., & Kim, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy022 · Cited by 158 · see citing works

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy

Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69 · see citing works

The impact of microbiome in urological diseases: a systematic review

Li, J. K. M., Chiu, P. K., & Ng, C. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02225-y · Cited by 16 · see citing works

Immune Checkpoint Inhibitors in Cancer Therapy

Shiravand, Y., Khodadadi, F., Kashani, S. M. A., Hosseini-Fard, S. R., Hosseini, S., Sadeghirad, H., Ladwa, R., O’Byrne, K., & Kulasinghe, A. (2022) · Current Oncology · doi:10.3390/curroncol29050247 · Cited by 1,353 · see citing works

Gut Microbiota in Colorectal Cancer: Biological Role and Therapeutic Opportunities

Pandey, H., Tang, D. W. T., Wong, S. H., & Lal, D. (2023) · Cancers · doi:10.3390/cancers15030866 · Cited by 165 · see citing works

Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC

Niu, M., Yi, M., Li, N., Luo, S., & Wu, K. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00211-8 · Cited by 125 · see citing works

Emerging role of human microbiome in cancer development and response to therapy: special focus on intestinal microflora

Sadrekarimi, H., Gardanova, Z. R., Bakhshesh, M., Ebrahimzadeh, F., Yaseri, A. F., Thangavelu, L. P., Hasanpoor, Z., Zadeh, F. A., & Kahrizi, M. S. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03492-7 · Cited by 125 · see citing works

Intestinal microbiota: a new force in cancer immunotherapy

Dai, Z., Zhang, J., Wu, Q., Fang, H., Shi, C., Li, Z., Lin, C., Tang, D., & Wang, D. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-00599-6 · Cited by 98 · see citing works

The Role of Immune Checkpoint Inhibitors in Cancer Therapy

Basudan, A. (2022) · Clinics and Practice · doi:10.3390/clinpract13010003 · Cited by 94 · see citing works

Manipulating Gut Microbiota Composition to Enhance the Therapeutic Effect of Cancer Immunotherapy

Yi, M., Jiao, D., Qin, S., Chu, Q., Li, A., & Wu, K. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419876351 · Cited by 69 · see citing works

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy

Almawash, S. (2025) · Cancers · doi:10.3390/cancers17050880 · Cited by 63 · see citing works

Predictive Biomarkers and Resistance Mechanisms of Checkpoint Inhibitors in Malignant Solid Tumors

Pavelescu, L. A., Enache, R. M., Roşu, O. A., Profir, M., Creţoiu, S. M., & Gașpar, B. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179659 · Cited by 55 · see citing works

Immune Cell Profiling of Peripheral Blood as Signature for Response During Checkpoint Inhibition Across Cancer Types

de Lima, V. A. B., Hansen, M., Spanggaard, I., Rohrberg, K. S., Hadrup, S. R., Lassen, U., & Svane, I. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.558248 · Cited by 50 · see citing works

Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges

Palma, M. (2025) · Vaccines · doi:10.3390/vaccines13040344 · Cited by 33 · see citing works

The human microbiome and genitourinary malignancies

Nicolaro, M., Portal, D. E., Shinder, B. M., Patel, H. V., & Singer, E. A. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-2976 · Cited by 31 · see citing works

The Microbiome and Its Implications in Cancer Immunotherapy

Choudhry, H. (2021) · Molecules · doi:10.3390/molecules26010206 · Cited by 31 · see citing works

Advances and mechanisms of gut microbiota modulation in enhancing immune checkpoint inhibitor efficacy

Chen, L., Li, B., Zu, M., Reis, R. L., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 22 · see citing works

Current approaches in glioblastoma multiforme immunotherapy

Aghajani, M., Jalilzadeh, N., Aghebati‐Maleki, A., Yari, A., Tabnak, P., Mardi, A., Saeedi, H., Maleki, L. A., & Baradaran, B. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03395-7 · Cited by 16 · see citing works

The impact of microbiome in urological diseases: a systematic review

Li, J. K. M., Chiu, P. K., & Ng, C. (2019) · International Urology and Nephrology · doi:10.1007/s11255-019-02225-y · Cited by 16 · see citing works

The role of intestinal flora on tumor immunotherapy: recent progress and treatment implications

Zhou, Y., Liu, X., Gao, W., Luo, X., Lv, J., Wang, Y., & Liu, D. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e23919 · Cited by 11 · see citing works

Gut microbiome and colorectal cancer: From pathogenesis to treatment

Lahouty, M., Fadaee, M., Aghaei, R., Alizadeh, F., Jafari, A., & Sharifi, Y. (2025) · Pathology - Research and Practice · doi:10.1016/j.prp.2025.156034 · Cited by 10 · see citing works

Prospect of bacteria for tumor diagnosis and treatment

Xu, Y., Zhao, C., Ma, X., & Zhang, H. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121215 · Cited by 9 · see citing works

Immune Checkpoint Inhibitor Therapy for Metastatic Melanoma: What Should We Focus on to Improve the Clinical Outcomes?

Hossain, S. M., Ly, K., Sung, Y. J., Braithwaite, A. W., & Li, K. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810120 · Cited by 8 · see citing works

Is obesity a disease?—the evolving concepts, cancer paradox and association with improved cancer immunotherapy efficacy

Cheng, M., & Gunderman, R. B. (2020) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2019.11.35 · Cited by 7 · see citing works

Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy

Kim, P., Joe, S., Kim, H., Jeong, H., Park, S., Song, J., Kim, W., & Lee, Y. G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26020856 · Cited by 5 · see citing works

Targeting tumor-draining lymph node to overcome resistance to cancer immunotherapy: an update

Lu, J., Yu, J., Xu, T., Li, Y., Chen, S., Zhou, Q., & Wang, L. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.126 · Cited by 5 · see citing works

Killing cancer takes guts: lessons learned from the manipulation of gut microbiome and immunotherapy for the future of urothelial carcinoma

Reddy, N., Lau, K., Naman, J., Lu, K., McGillivary, E., Salmasi, A., Liss, M. A., & Stewart, T. F. (2026) · Oncoimmunology · doi:10.1080/2162402x.2025.2611458 · Cited by 2 · see citing works

Non-small Cell Lung Cancer, Immunotherapy and the Influence of Gut Microbiome

Raziq, M. F., Manzoor, H., & Kayani, M. U. R. (2025) · Current Microbiology · doi:10.1007/s00284-025-04408-6 · Cited by 3 · see citing works

Associations Between the Gut Microbiome and Outcomes in Autologous Stem Cell Transplantation: A Systematic Review

Pitts, E., Grainger, B. T., McKenzie, D., & Fiorenza, S. (2025) · Microorganisms · doi:10.3390/microorganisms13102302 · Cited by 2 · see citing works

Immune checkpoint inhibitor associated lichenoid eruptions: a review of non-steroidal systemic maintenance therapies

Tran, R., Toulmin, S. A., Allais, B. S., Brag, K., & Iriarte, C. (2025) · Supportive Care in Cancer · doi:10.1007/s00520-025-10054-2 · Cited by 2 · see citing works

Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy

Rolig, A. S., Ziglari, T., McGee, G. H., Kasiewicz, M. J., Kolbaba, K., Simons, N. D., Pucilowska, J., Sfanos, K. S., & Redmond, W. L. (2026) · Scientific Reports · doi:10.1038/s41598-026-39758-z · Cited by 2 · see citing works

Unmet needs in autoimmune liver diseases

Chang, C. C.-C., Tanaka, A., & Gershwin, M. E. (2019) · Journal of Digestive Diseases · doi:10.1111/1751-2980.12785

Author Index

Authors, V. (2013) · Current Oncology · doi:10.3747/co.20.1906

The Impact of Fecal Diversion on Immune Checkpoint Inhibitor Adverse Gastrointestinal Toxicities

Adames, S. M., Naz, S., Dai, J., Wang, Y., & Thomas, A. S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14134711

Gut microbiota influences the efficiency of immune checkpoint inhibitors by modulating the immune system (Review)

Jiang, H., & Zhang, Q. (2024) · Oncology Letters · doi:10.3892/ol.2024.14221 · Cited by 34 · see citing works

Modulation of Gut Microbiota to Enhance Effect of Checkpoint Inhibitor Immunotherapy

Wu, J., Wang, S., Zheng, B. J., Qiu, X., Wang, H., & Chen, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669150 · Cited by 70 · see citing works

The role of the gut microbiome in regulating the response to immune checkpoint inhibitor therapy

Dean, N. J., d’Arienzo, P. D., Ibraheim, H., Lee, K. A., Olsson-Brown, A. C., Pinato, D. J., & Powell, N. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101944 · Cited by 8 · see citing works

Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors

Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 25 · see citing works

Gut microbiome in modulating immune checkpoint inhibitors

Li, X., Zhang, S., Guo, G., Han, J., & Yu, J. Q. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104163 · Cited by 172 · see citing works